Application of STX10 in treatment and prognosis evaluation of kidney cancer

By revealing the significant upregulation of STX10 in ccRCC, and utilizing STX10 inhibitors and detection reagents, the challenge of prognostic assessment of ccRCC was solved, enabling precision treatment and improved prognosis, and providing new diagnostic and treatment methods for renal cell carcinoma.

CN122038569APending Publication Date: 2026-05-15THE SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY
0 Cites 0 Cited by

Patent Information

Application Number
CN202610089173.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-01-22
Publication Date
2026-05-15

AI Technical Summary

Technical Problem

In the current technology, the risk of tumor recurrence or metastasis after surgery is difficult to predict in patients with clear cell renal cell carcinoma (ccRCC). Traditional clinical parameters cannot be accurately assessed, some patients develop resistance to immune checkpoint inhibitors, and there is a lack of effective biomarkers to predict prognosis and guide individualized treatment.

Method used

Through bioinformatics analysis and in vitro experiments, it was revealed that STX10 is significantly upregulated in ccRCC. As a novel biomarker for predicting the prognosis of ccRCC, STX10 inhibitors such as siRNA, shRNA, and sgRNA are provided, along with reagents and kits for detecting STX10 expression levels, for auxiliary diagnosis and prognostic assessment. Furthermore, STX10 can be used in combination with anti-PD-1 antibodies to improve treatment sensitivity.

Benefits of technology

STX10 can serve as an independent prognostic factor for ccRCC. By inhibiting STX10 expression or activity, the development of renal cell carcinoma can be significantly suppressed, patient survival can be prolonged, prognosis can be improved, and individualized treatment strategies and targeted therapy can be provided.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to application of STX10 in treatment and prognosis evaluation of kidney cancer. The key effect of the STX10 in the renal clear cell carcinoma is emphasized, and the fact that the expression of the STX10 in ccRCC is remarkably up-regulated is revealed. Overexpression of the STX10 promotes proliferation and migration of ccRCC cells, is an independent risk factor of poor OS, PFI and DSS of the ccRCC and is closely related to poor immunotherapy response, it is clear that the STX10 can serve as a prognosis biomarker and a treatment target of the ccRCC, and development of kidney cancer can be obviously inhibited, the survival rate of patients can be prolonged and prognosis can be improved by inhibiting the STX10 or reducing the biological activity of the STX10. Related molecular mechanisms in the occurrence and development process of the kidney cancer are enriched, sufficient scientific basis and theoretical basis are provided for exploring new kidney cancer diagnosis, prognosis judgment and treatment molecular targets and developing new targeted drugs, accurate treatment can be better achieved, and important social value and scientific significance are achieved.
Need to check novelty before this filing date? Find Prior Art